Transactions
2
Insider / Cigna Group
McClellan Mark B.
Director at Cigna Group
- Company
- Cigna Group
- First filing on record
- April 24, 2026
- Latest trade on record
- April 23, 2026
- SEC filings
- EDGAR ↗
McClellan Mark B., Director at Cigna Group, has disclosed 2 transactions in JNJ, CI since April 24, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed April 27, 2026, 4 days after the trade.
Open-market buys
0
Sales
0
Avg. disclosure lag
3.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months McClellan Mark B. reported 2 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 2 | 1,757 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | Other A | April 23, 2026 | April 27, 2026 | 4d | 975 | — | — | derivative | Form 4 ↗ | |
| CI | Other A | April 22, 2026 | April 24, 2026 | 2d | 782 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| April 27, 2026 | Form 4 | 0000200406-26-000102 | 1 | published | EDGAR ↗ |
| April 24, 2026 | Form 4 | 0001739940-26-000036 | 1 | published | EDGAR ↗ |
Other insiders at Cigna Group
- Wolk Joseph J Exec VP, CFO 34 rows
- Schmid Timothy EVP, WW Chair, MedTech 31 rows
- Cordani David Chairman & CEO 27 rows
- Broadhurst Vanessa EVP, Global Corp Affairs 25 rows
- Swanson James D. EVP, CIO 24 rows
- Wengel Kathryn E EVP, Chief TO and Risk Officer 24 rows
- Duato Joaquin CEO and Chairman of the Board 23 rows
- Taubert Jennifer L Director 23 rows
- Forminard Elizabeth EVP, Chief Legal Officer 22 rows
- REED JOHN C EVP, Innovative Medicine, R&D 21 rows
Everyone on file, with contracts and lobbying under the company's name: Cigna Group.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 2 | April 24, 2026 | April 27, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.